Telix Pharmaceuticals Ltd. ( (AU:TLX) ) has provided an update.
Telix Pharmaceuticals Limited is hosting an investor webinar to showcase its late-stage and next-generation radiotherapeutic candidates in urologic oncology, focusing on prostate and kidney cancers. The event will feature discussions by prominent medical professionals on Telix’s leading radio antibody-drug conjugate therapy candidates, including TLX591 for prostate cancer and TLX250 in combination with immunotherapy for renal cell carcinoma. This initiative underscores Telix’s commitment to advancing its oncology pipeline and highlights its strategic positioning in the biopharmaceutical industry.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company that focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Canada, Europe, and Japan. The company is developing a portfolio of clinical and commercial stage products aimed at addressing significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 26.47%
Average Trading Volume: 4,579
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $5.97B
Learn more about TLX stock on TipRanks’ Stock Analysis page.